ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: PUB109

Comparison of Cognitive Impairment by Montreal Cognitive Assessment (MoCA) with Sarcopenia in Hemodialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Lee, Heeryong, Maryknoll medical center, Busan, Korea (the Republic of)
  • Ahn, Jeongmyung, Maryknoll medical center, Busan, Korea (the Republic of)
  • Lee, Dong Ryeol, Maryknoll medical center, Busan, Korea (the Republic of)
  • Jeon, Mi young, Maryknoll medical center, Busan, Korea (the Republic of)
  • Park, Hongmin, Hallym university medical center, Seoul, Korea (the Republic of)
Background

Sarcopenia has been implicated in the increased risk for cognitive impairment. Hemodialysis patients are at increased risk for sarcopenia. In this cross-sectional study, we investigated the relationship of sarcopenia with cognitive impairment in hemodialysis patients.

Methods

Total 118 hemodialysis patients, 64 men and 54 women, aged 40 years or older were included in the study. The Montreal cognitive assessment (MoCA) was used to assess cognitive performance. The MoCA consists of seven separate items (visuospatial/executive, naming, attention, language, abstraction, delayed recall, orientation). Demographics, body composition, and history of cardiovascular diseases were assessed as covariates. The cut-off of the MoCA score of the diagnosis of cognitive impairment was 22 points. The European Working Group on Sarcopenia in Older People (EWGOP) diagnostic criteria were applied to diagnose sarcopenia. The muscle mass was measured using Bioimpedance analysis and muscle strength was measured using handgrip strength.

Results

Of the patients included, 55 (women 36.4 %) were diagnosed with sarcopenia (46.6 %). The incidence of sarcopenia was higher in older patients (67.0 vs 70.0, p=0.046), but there was no difference in other variables. There was significant difference in the cognitive impairment ratio according to the presence or absence of sarcopenia (31 (56.3%) vs 28 (44.4%), p=0.046). Odd ratio (OR) and 95% confidence interval (95% CI) of cognitive impairment was calculated sarcopenia status. Compared to non-sarcopenic, sarcopenic hemodialysis patients had the ORs of 1.09 (95% CI of 1.05-1.15, p=0.030) for cognitive impairment.

Conclusion

Sarcopenia was significantly associated with cognitive impairment in hemodialysis patients. Cognitive impairment reduces the quality of life of hemodialysis patients. Therefore, it is important to prevent sarcopenia, which can cause cognitive impairment in hemodialysis patients.